Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?

Lung Cancer. 2013 Jun;80(3):352-3. doi: 10.1016/j.lungcan.2013.01.023. Epub 2013 Feb 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug-Related Side Effects and Adverse Reactions
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Protein Kinase Inhibitors / administration & dosage
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*
  • Quinazolines / pharmacokinetics

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride